Spectrum drops experimental drug for enlarged prostate

01/27/2010 | Reuters

Spectrum Pharmaceuticals decided to abandon development of ozarelix, its experimental treatment for benign prostatic hypertrophy, after the drug fared poorly in a midstage clinical trial. The move is expected to save Spectrum more than $40 million.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Fort Worth, TX
Senior Scientist - Cell Engineering Group
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC